Intratumoural administration of dendritic cell

Hostile environment and help by gene therapy

Eduardo Huarte, Iñigo Tirapu, Ainhoa Arina, Maria Vera Ugalde, Carlos Alfaro, Oihana Murillo, Belén Palencia, Victoria Busto, Verónica Marín, Guillermo Mazzolini, Ignacio Melero

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Like paratroopers in special operations, dendritic cells (DCs) can be deployed behind the enemy borders of malignant tissue to ignite an antitumour immune response. 'Cross-priming T cell responses' is the code name for their mission, which consists of taking up antigen from transformed cells or their debris, migrating to lymphoid tissue ferrying the antigenic cargo, and meeting specific T cells. This must be accomplished in such an immunogenic manner that specific T lymphocytes would mount a robust enough response as to fully reject the malignancy. To improve their immunostimulating activity, local gene therapy can be very beneficial, either by transfecting DCs with genes enhancing their performance, or by preparing tumour tissue with proinflammatory mediators. In addition, endogenous DCs from the tumour host can be attracted into the malignant tissue following transfection of certain chemokine genes into tumour cells. On their side, tumour stroma and malignant cells set up a hostile immunosuppressive environment for artificially released or attracted DCs. This milieu is usually rich in transforming growth factor-β, vascular endothelial growth factor, and IL-10, -6 and -8, among other substances that diminish DC performance. Several molecular strategies are being devised to interfere with the immunosuppressive actions of these substances and to further enhance the level of anticancer immunity achieved after artificial release of DCs intratumourally.

Original languageEnglish (US)
Pages (from-to)7-22
Number of pages16
JournalExpert Opinion on Biological Therapy
Volume5
Issue number1
DOIs
StatePublished - Jan 2005
Externally publishedYes

Fingerprint

Gene therapy
Genetic Therapy
Dendritic Cells
T-cells
Tumors
Tissue
Neoplasms
Immunosuppressive Agents
T-Lymphocytes
Genes
Cross-Priming
Transforming Growth Factors
Lymphoid Tissue
Chemokines
Debris
Interleukin-10
Vascular Endothelial Growth Factor A
Names
Transfection
Immunity

Keywords

  • Anticancer
  • Delivery
  • Dendritic cells
  • Gene therapy
  • Intratumoural administration

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Intratumoural administration of dendritic cell : Hostile environment and help by gene therapy. / Huarte, Eduardo; Tirapu, Iñigo; Arina, Ainhoa; Vera Ugalde, Maria; Alfaro, Carlos; Murillo, Oihana; Palencia, Belén; Busto, Victoria; Marín, Verónica; Mazzolini, Guillermo; Melero, Ignacio.

In: Expert Opinion on Biological Therapy, Vol. 5, No. 1, 01.2005, p. 7-22.

Research output: Contribution to journalReview article

Huarte, E, Tirapu, I, Arina, A, Vera Ugalde, M, Alfaro, C, Murillo, O, Palencia, B, Busto, V, Marín, V, Mazzolini, G & Melero, I 2005, 'Intratumoural administration of dendritic cell: Hostile environment and help by gene therapy', Expert Opinion on Biological Therapy, vol. 5, no. 1, pp. 7-22. https://doi.org/10.1517/14712598.5.1.7
Huarte, Eduardo ; Tirapu, Iñigo ; Arina, Ainhoa ; Vera Ugalde, Maria ; Alfaro, Carlos ; Murillo, Oihana ; Palencia, Belén ; Busto, Victoria ; Marín, Verónica ; Mazzolini, Guillermo ; Melero, Ignacio. / Intratumoural administration of dendritic cell : Hostile environment and help by gene therapy. In: Expert Opinion on Biological Therapy. 2005 ; Vol. 5, No. 1. pp. 7-22.
@article{122c122f020745a5b27b141312371a44,
title = "Intratumoural administration of dendritic cell: Hostile environment and help by gene therapy",
abstract = "Like paratroopers in special operations, dendritic cells (DCs) can be deployed behind the enemy borders of malignant tissue to ignite an antitumour immune response. 'Cross-priming T cell responses' is the code name for their mission, which consists of taking up antigen from transformed cells or their debris, migrating to lymphoid tissue ferrying the antigenic cargo, and meeting specific T cells. This must be accomplished in such an immunogenic manner that specific T lymphocytes would mount a robust enough response as to fully reject the malignancy. To improve their immunostimulating activity, local gene therapy can be very beneficial, either by transfecting DCs with genes enhancing their performance, or by preparing tumour tissue with proinflammatory mediators. In addition, endogenous DCs from the tumour host can be attracted into the malignant tissue following transfection of certain chemokine genes into tumour cells. On their side, tumour stroma and malignant cells set up a hostile immunosuppressive environment for artificially released or attracted DCs. This milieu is usually rich in transforming growth factor-β, vascular endothelial growth factor, and IL-10, -6 and -8, among other substances that diminish DC performance. Several molecular strategies are being devised to interfere with the immunosuppressive actions of these substances and to further enhance the level of anticancer immunity achieved after artificial release of DCs intratumourally.",
keywords = "Anticancer, Delivery, Dendritic cells, Gene therapy, Intratumoural administration",
author = "Eduardo Huarte and I{\~n}igo Tirapu and Ainhoa Arina and {Vera Ugalde}, Maria and Carlos Alfaro and Oihana Murillo and Bel{\'e}n Palencia and Victoria Busto and Ver{\'o}nica Mar{\'i}n and Guillermo Mazzolini and Ignacio Melero",
year = "2005",
month = "1",
doi = "10.1517/14712598.5.1.7",
language = "English (US)",
volume = "5",
pages = "7--22",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Intratumoural administration of dendritic cell

T2 - Hostile environment and help by gene therapy

AU - Huarte, Eduardo

AU - Tirapu, Iñigo

AU - Arina, Ainhoa

AU - Vera Ugalde, Maria

AU - Alfaro, Carlos

AU - Murillo, Oihana

AU - Palencia, Belén

AU - Busto, Victoria

AU - Marín, Verónica

AU - Mazzolini, Guillermo

AU - Melero, Ignacio

PY - 2005/1

Y1 - 2005/1

N2 - Like paratroopers in special operations, dendritic cells (DCs) can be deployed behind the enemy borders of malignant tissue to ignite an antitumour immune response. 'Cross-priming T cell responses' is the code name for their mission, which consists of taking up antigen from transformed cells or their debris, migrating to lymphoid tissue ferrying the antigenic cargo, and meeting specific T cells. This must be accomplished in such an immunogenic manner that specific T lymphocytes would mount a robust enough response as to fully reject the malignancy. To improve their immunostimulating activity, local gene therapy can be very beneficial, either by transfecting DCs with genes enhancing their performance, or by preparing tumour tissue with proinflammatory mediators. In addition, endogenous DCs from the tumour host can be attracted into the malignant tissue following transfection of certain chemokine genes into tumour cells. On their side, tumour stroma and malignant cells set up a hostile immunosuppressive environment for artificially released or attracted DCs. This milieu is usually rich in transforming growth factor-β, vascular endothelial growth factor, and IL-10, -6 and -8, among other substances that diminish DC performance. Several molecular strategies are being devised to interfere with the immunosuppressive actions of these substances and to further enhance the level of anticancer immunity achieved after artificial release of DCs intratumourally.

AB - Like paratroopers in special operations, dendritic cells (DCs) can be deployed behind the enemy borders of malignant tissue to ignite an antitumour immune response. 'Cross-priming T cell responses' is the code name for their mission, which consists of taking up antigen from transformed cells or their debris, migrating to lymphoid tissue ferrying the antigenic cargo, and meeting specific T cells. This must be accomplished in such an immunogenic manner that specific T lymphocytes would mount a robust enough response as to fully reject the malignancy. To improve their immunostimulating activity, local gene therapy can be very beneficial, either by transfecting DCs with genes enhancing their performance, or by preparing tumour tissue with proinflammatory mediators. In addition, endogenous DCs from the tumour host can be attracted into the malignant tissue following transfection of certain chemokine genes into tumour cells. On their side, tumour stroma and malignant cells set up a hostile immunosuppressive environment for artificially released or attracted DCs. This milieu is usually rich in transforming growth factor-β, vascular endothelial growth factor, and IL-10, -6 and -8, among other substances that diminish DC performance. Several molecular strategies are being devised to interfere with the immunosuppressive actions of these substances and to further enhance the level of anticancer immunity achieved after artificial release of DCs intratumourally.

KW - Anticancer

KW - Delivery

KW - Dendritic cells

KW - Gene therapy

KW - Intratumoural administration

UR - http://www.scopus.com/inward/record.url?scp=19944429072&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944429072&partnerID=8YFLogxK

U2 - 10.1517/14712598.5.1.7

DO - 10.1517/14712598.5.1.7

M3 - Review article

VL - 5

SP - 7

EP - 22

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 1

ER -